<noframes id="zd9f3">

    <address id="zd9f3"></address>

    <address id="zd9f3"></address>
    <address id="zd9f3"></address>

    <address id="zd9f3"><nobr id="zd9f3"><meter id="zd9f3"></meter></nobr></address>
    1. Antibody-drug Conjugate/ADC Related
    2. ADC Linker

    ADC Linker

    Antibody-drug conjugates (ADCs) consist of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker. An appropriate linker between the antibody and the cytotoxic drug provides a specific bridge, and thus helps the antibody to selectively deliver the cytotoxic drug to tumor cells and accurately releases the cytotoxic drug at tumor sites. In addition to conjugation, the linkers maintain ADCs’ stability during the preparation and storage stages of the ADCs and during the systemic circulation period.

    The ADCs currently undergoing clinical evaluation contain linkers are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, such as reduction in the cytoplasm, exposure to acidic conditions in the lysosome, or cleavage by specific proteases within the cell. Noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule, which will retain the linker and the amino acid by which it was attached to the antibody.

    The selection of linker is target dependent, based on the knowledge of the internalization and degradation of the antibody-target antigen complex, and a preclinical in vitro and in vivo activity comparison of conjugates. Moreover, the choice of a linker is also influenced by which cytotoxin is used, as each molecule has different chemical constraints, and frequently the drug structure lends itself to a specific linker.

    ADC Linker 相关产品 (12):

    Cat. No. Product Name Effect Purity
    • HY-78738
      MC-Val-Cit-PAB 99.66%
      MC-Val-Cit-PAB是可被组织蛋白酶切割的ADC连接桥,用于制备抗体-药物偶联物。 美国FDA批准的药物,如brentuximab vedotin使用了该连接桥。
    • HY-12362
      Val-cit-PAB-OH 99.64%
    • HY-20336
      Mc-Val-Cit-PABC-PNP 98.68%
      Mc-Val-Cit-PABC-PNP是用于合成抗体-药物偶联物 (ADCs) 的,可切割的组织蛋白酶连接桥 (ADC linker)。
    • HY-41189
      Fmoc-Val-Cit-PAB-PNP是一种多肽前体药物连接子,是抗体偶联药物 (ADC) 的常用连接桥
    • HY-19318
      Fmoc-Val-Cit-PAB 98.13%
    • HY-114430
      Fmoc-Phe-Lys(Boc)-PAB-PNP 是抗体偶联药物 (ADC) 的常用连接桥。
    • HY-112899
      DC1是 DNA 小沟结合的烷基化酶 CC-1065 的类似物,是可用于靶向治疗癌症的细胞毒性 DNA 烷基化酶的抗体偶联物。
    • HY-112898
      DC1-Sme 是靶向治疗癌症的,细胞毒性DNA烷基化磷酸盐抗体偶联药物前体。
    • HY-21210
      6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)-
      6-Quinoxalinecarboxylic acid, 2,3-bis(bromomethyl)- 是抗体偶联药物 (ADC) 的连接桥。
    • HY-78961
      6-Maleimidohexanoic acid N-hydroxysuccinimide ester 99.96%
      6-Maleimidohexanoic acid N-hydroxysuccinimide ester(ECMS)是抗体偶联药物(ADC)中常用保护基团。
    • HY-20560
    • HY-111434
      UAA crosslinker 1
      UAA crosslinker 1可充当pylRS/tRNA对的底物,能够掺入靶蛋白中。
    Isoform Specific Products

    Your Search Returned No Results.

    Sorry. There is currently no product that acts on isoform together.

    Please try each isoform separately.